<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-OOC-16008448</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2016-05-09</date_registration>
      <primary_sponsor>Department of Hematology, Xinqiao Hospital, Third Military Medical University</primary_sponsor>
      <public_title>Effect of chimeric antigen receptor T cells followed by allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute lymphoblast leukemia: A phase II, unblind, uncotroll clincial  trial in a single center </public_title>
      <acronym />
      <scientific_title>Effect of chimeric antigen receptor T cells followed by allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute lymphoblast leukemia: A phase II, unblind, uncotroll clincial  trial in a single center </scientific_title>
      <Scientific_acronym />
      <date_enrolment>2016-04-10</date_enrolment>
      <type_enrolment />
      <target_size>experimental group:22;</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=14313</url>
      <study_type>Observational study</study_type>
      <study_design>Case series</study_design>
      <phase>Other</phase>
      <hc_freetext>relapsed/refractory acute lymphoblast leukemia</hc_freetext>
      <i_freetext>experimental group:Chimeric antigen receptor T cells followed by allogeneic hematopoietic stem cell transplantation;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Zhang Cheng</firstname>
        <middlename />
        <lastname />
        <address>183 Xinqiao Main Street, Shapingba District, Chongqing</address>
        <city />
        <country1 />
        <zip>400037</zip>
        <telephone>+86 13098770350</telephone>
        <email>chzhang2014@163.com</email>
        <affiliation>Department of Hematology, Xinqiao Hospital, Third Military Medical University</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Zhang Cheng</firstname>
        <middlename />
        <lastname />
        <address>183 Xinqiao Main Street, Shapingba District, Chongqing</address>
        <city />
        <country1 />
        <zip>400037</zip>
        <telephone>+86 13098770350</telephone>
        <email>chzhang2014@163.com</email>
        <affiliation>Department of Hematology, Xinqiao Hospital, Third Military Medical University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1) Male or Female; Aged below 55 years;
2) Refractory/relapsed acute lymphoblast leukemia with CD19 expression and no other effectvie way to select;
3) The estimated survial is over three months;
4) ECOG performance status of &lt;=2 at study entry;
5) The important organs are function, such as heart and brain;
6)Understand and voluntarily sign an informed consent form.</inclusion_criteria>
      <agemin>0</agemin>
      <agemax>55</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1) The uncontrol infetion, HBV and HCV are positive;
2) The patients received any cell immunotherapy in the past.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>One-year disease-free survival;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Overall Survival;The Rate of graft-versus-host disease;The rate of infection;</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>The special foundation for the </source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2016-04-28</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>